MedTrace Logo

Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma

NCT03602131 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-07-26

No results posted yet for this study

Summary

This study is to explore the efficacy and safety of ChiCGB conditioning therapy in patients with high-risk Hodgkin and non-Hodgkin lymphoma.

Conditions

Interventions

DRUG

Chidamide

30 mg oral twice weekly for 2 weeks

DRUG

Cladribine

6 mg/m2 intravenously once daily for 5 days

DRUG

gemcitabine

2500 mg/m2 intravenously twice weekly for 1 week

DRUG

Busulfan

3.2 mg/kg intravenously once daily for 4 days

PROCEDURE

Autologous hematopoietic stem cell transplantation

autologous hematopoietic stem cells infusion after ChiCGB chemotherapy

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2020-12-30
Completion
2021-03-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03602131 on ClinicalTrials.gov